In studies, the most serious side effects of the combination olaratumab/doxorubicin were [[neutropenia]] (low count of [[neutrophil]] white blood cells) with a severity of grade 3 or 4 in 55% of patients, and musculoskeletal pain grade 3 or 4 in 8% of patients. Common milder side effects were [[lymphopenia]], headache, diarrhoea, [[nausea]] and vomiting, [[mucositis]], and reactions at the infusion site;<ref name="EPAR" /> all typical effects of cancer therapies.

 

